178 related articles for article (PubMed ID: 32538221)
1. The crosstalk between antiretrovirals pharmacology and HIV drug resistance.
Giacomelli A; Pezzati L; Rusconi S
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):739-760. PubMed ID: 32538221
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1.
Pham HT; Yoo S; Mesplède T
Expert Opin Investig Drugs; 2020 Mar; 29(3):273-283. PubMed ID: 31994943
[No Abstract] [Full Text] [Related]
4. HIV antiretroviral drug resistance in Africa.
Nkengasong JN; Adje-Toure C; Weidle PJ
AIDS Rev; 2004; 6(1):4-12. PubMed ID: 15168736
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.
Nolan M; Fowler MG; Mofenson LM
J Acquir Immune Defic Syndr; 2002 Jun; 30(2):216-29. PubMed ID: 12045685
[TBL] [Abstract][Full Text] [Related]
6. Fostemsavir for the treatment of HIV.
Seval N; Frank C; Kozal M
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
[No Abstract] [Full Text] [Related]
7. Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.
Katusiime C; Ocama P; Kambugu A
Afr Health Sci; 2014 Sep; 14(3):679-81. PubMed ID: 25352888
[TBL] [Abstract][Full Text] [Related]
8. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
Marconi VC; Sunpath H; Lu Z; Gordon M; Koranteng-Apeagyei K; Hampton J; Carpenter S; Giddy J; Ross D; Holst H; Losina E; Walker BD; Kuritzkes DR;
Clin Infect Dis; 2008 May; 46(10):1589-97. PubMed ID: 18419495
[TBL] [Abstract][Full Text] [Related]
10. High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents.
Soumah A; Avettand-Fenoel V; Veber F; Moshous D; Mahlaoui N; Blanche S; Frange P
Med Mal Infect; 2020 May; 50(3):269-273. PubMed ID: 31722862
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.
Clarke DF; Penazzato M; Capparelli E; Cressey TR; Siberry G; Sugandhi N; Mirochnick M;
Expert Rev Clin Pharmacol; 2018 Jan; 11(1):83-93. PubMed ID: 29039686
[TBL] [Abstract][Full Text] [Related]
12. Management of HIV infection after triple class failure.
Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A
New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in HIV-1.
Kuritzkes DR
Curr Opin Virol; 2011 Dec; 1(6):582-9. PubMed ID: 22162985
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world.
Frentz D; Boucher CA; van de Vijver DA
AIDS Rev; 2012; 14(1):17-27. PubMed ID: 22297501
[TBL] [Abstract][Full Text] [Related]
15. The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico.
Calva JJ; Larrea S; Tapia-Maltos MA; Ostrosky-Frid M; Lara C; Aguilar-Salinas P; Rivera H; Ramírez JP
AIDS Res Hum Retroviruses; 2017 Jul; 33(7):675-680. PubMed ID: 28094565
[TBL] [Abstract][Full Text] [Related]
16. The Impact of HIV-1 Drug Escape on the Global Treatment Landscape.
Collier DA; Monit C; Gupta RK
Cell Host Microbe; 2019 Jul; 26(1):48-60. PubMed ID: 31295424
[TBL] [Abstract][Full Text] [Related]
17. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
Clotet B
AIDS Rev; 2004; 6(3):123-30. PubMed ID: 15595429
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
Calcagno A; D'Avolio A; Bonora S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
De Luca A; Hamers RL; Schapiro JM
J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
